Abstract
Astrocytes perform a range of homeostatic and regulatory tasks that are critical for normal functioning of the central nervous system. In response to an injury or disease, astrocytes undergo a pronounced transformation into a reactive state that involves changes in the expression of many genes and dramatically changes astrocyte morphology and functions. This astrocyte reactivity is highly dependent on the initiating insult and pathological context. C3a is a peptide generated by the proteolytic cleavage of the third complement component. C3a has been shown to exert neuroprotective effects, stimulate neural plasticity and promote astrocyte survival but can also contribute to synapse loss, Alzheimer’s disease type neurodegeneration and blood–brain barrier dysfunction. To test the hypothesis that C3a elicits differential effects on astrocytes depending on their reactivity state, we measured the expression of Gfap, Nes, C3ar1, C3, Ngf, Tnf and Il1b in primary mouse cortical astrocytes after chemical ischemia, after exposure to lipopolysaccharide (LPS) as well as in control naïve astrocytes. We found that C3a down-regulated the expression of Gfap, C3 and Nes in astrocytes after ischemia. Further, C3a increased the expression of Tnf and Il1b in naive astrocytes and the expression of Nes in astrocytes exposed to LPS but did not affect the expression of C3ar1 or Ngf. Jointly, these results provide the first evidence that the complement peptide C3a modulates the responses of astrocytes in a highly context-dependent manner.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Astrocytes provide trophic support to neurons, regulate neuronal functioning and maintain brain tissue homeostasis by e.g. neurotransmitter uptake, metabolite recycling and regulation of water balance [1]. In response to infection, acute injury such as trauma or stroke, as well as chronic neurodegenerative processes, astrocytes undergo a transformation into a reactive state that is aimed at limiting tissue damage and restoration of homeostasis, and involves changes in the expression of many genes as well as alteration of astrocyte morphology and functions [2]. This astrocyte reactivity is, however, highly dependent on the initiating insult and pathological context [3] and may even be maladaptive or inhibit neuroregeneration [4,5,6,7,8,9,10].
Astrocytes responding to ischemia upregulate many neurotrophic genes [3] and promote neuronal survival, repair and recovery [11,12,13,14,15,16]. Systemic inflammation, typically modelled by exposure to endotoxin lipopolysaccharide (LPS), leads to the induction of reactive astrocytes that express high amounts of the third complement component (C3) [17] and lipocalin-2, and increase their secretion of long-chain saturated lipids that are toxic to neurons and oligodendrocytes [18]. In contrast to microglia, rodent astrocytes do not respond to LPS directly as they lack the required receptors and down-stream signaling components [17]. Instead, LPS exerts its effects on astrocytes via microglia-derived complement component C1q, interleukin-1a and tumor necrosis factor (TNF) [17]. Astrocytes expressing high levels of C3 are also found in aged brain [19] and in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis [17], or in a deafferented hippocampus [20]. In Alzheimer’s disease, C3 is also expressed by microglia and C3 secreted by both microglia and astrocytes is involved in reciprocal signaling between these glial populations to produce excess C3 [21]. Although microglia and astrocytes express complement receptors that can bind C3-derived ligands [22] that could be involved in this process, the specific receptor or mechanism for this C3-mediated reciprocal signaling between microglia and astrocytes remains to be identified.
Proteolytic cleavage of C3 by complement cascade-derived C3 convertases and other membrane-associated or serine proteases generates a larger C3b fragment and smaller C3a fragment [23]. C3b can augment complement activation and functions as opsonin in the phagocytosis of synapses and clearance of cell debris by microglia [24, 25]. Through binding to a seven transmembrane domain G-protein-coupled C3a receptor (C3aR), C3a promotes astrocyte survival [26], regulates neuronal maturation, differentiation and migration of neural stem/progenitor cells [27, 28], stimulates adult neurogenesis [29], and is neuroprotective [30,31,32]. In the post-ischemic brain, C3a stimulates neural plasticity and recovery [33, 34]. However, C3aR signaling has been shown to also contribute to Alzheimer’s disease type neurodegeneration [35, 36], virus-induced synapse loss and memory impairment [37], and blood–brain barrier dysfunction associated with aging [38]. Given these wide-ranging and even opposite effects of C3a-C3aR in the brain and our previous finding that the effects of C3a on neural progenitor cell migration are dependent on the concentration of stromal-derived factor [27], we hypothesized that the effects of C3a on astrocytes are context-dependent. To test this hypothesis, we cultured naïve (unchallenged) primary mouse astrocytes, astrocytes subjected to ischemia and astrocytes exposed to LPS in the presence or absence of C3a and used quantitative real time PCR (qRT-PCR) to determine the expression of genes coding for intermediate filament (nanofilament) proteins glial fibrillary acidic protein (GFAP) and nestin, C3aR, C3, nerve growth factor (NGF), tumor necrosis factor (TNF) and interleukin-1β (IL1β).
Materials and Methods
Primary Astrocyte Culture Preparation
Primary astrocyte cultures were prepared from postnatal day 2 C57BL/6NCr mice (Charles River) as previously described [39] with minor modifications. Briefly, mice were decapitated and brains were dissected under sterile conditions. After removal of meninges, cortices were enzymatically digested with 0.25% trypsin (Sigma-Aldrich) and DNase I (0.01 mg/ml, Sigma-Aldrich) in Hank's Balanced Salt Solution for 30 min at 37 °C. After dissociation, cells were centrifuged at 800 g for 5 min and resuspended in astrocyte-specific medium Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, California) with 10% fetal bovine serum (FBS, Life Technologies, Paisley, UK), 1% l-glutamine (Invitrogen, Carlsbad, California), and 1% penicillin–streptomycin (Invitrogen, Carlsbad, California). Cells were plated on noncoated 24- well culture plates (Sarstedt, Nümbrecht, Germany) and cultured for 7 days in a humidified CO2 incubator at 37 °C; medium was replaced every 3rd day until treatment. Using immunostaining with antibodies against Iba-1 as previously described [40], we determined that the cultures contained 1.76 ± 0.06% (n = 4) of microglial cells.
Chemical Ischemia Induction and Lipopolysaccharide (LPS) Exposure
Chemical ischemia was induced as previously described [26] using 1 mM NaN3 and 2 mM 2-deoxy-D-glucose in saline (140.7 mM NaCl, 3 mM KCl, 1.2 mM MgSO4, 1 mM CaCl2, 2 mM NaH2PO4, 20 mM HEPES at pH 7.4) for 2 h. Thereafter, cells were allowed to recover in serum-free DMEM with B27 supplement (Gibco B27 supplement) in the presence or absence of 100 nM purified human C3a (Complement Technology, Tyler, Texas, USA) for 4 h. For LPS exposure experiments, cells were cultured in serum-free DMEM with B27 supplement containing LPS (1 ng/μL) for 6 h in the presence or absence of 100 nM purified human C3a. The same culture preparation was used for chemical ischemia and LPS exposure in a parallel experiment. In addition, an independent experiment using chemical ischemia was performed. Non-challenged naïve astrocytes were included as control; 4 replicates per treatment were used for each experiment.
RNA Extraction and qRT-PCR
RNA extraction and qRT-PCR were performed as described previously [26]. Total RNA from each well was extracted using Qiagen RNeasy Micro Kit with DNase treatment (QIAGEN, Hilden, Germany). Reverse transcription was performed using cDNA synthesis kit (Takara Bio, Saint-Germain-en-Laye, France) using the following temperature profile: 22 °C for 5 min, 42 °C for 30 min, 85 °C for 5 min. RT-qPCR was conducted using TATAA SYBR Grand Mastermix ROX kit (TATAA Biocenter, Gothenburg, Sweden) and using the following temperature profile: 95 °C for 30 s followed by 40 cycles at 95 °C for 3 s, 60 °C for 15 s, and 72 °C for 10 s, and detected by Quant Studio Real-Time PCR System (Life Technologies). Reference genes Hprt1 (PM26FM) and Actb (PM20L) from the Mouse Endogenous Control Gene Panel (TATAA Biocenter) were used for data normalization. The following primer sequences were used: C3aR: C3ar1_fwd TGTTGGTGGCTCGCAGAT, C3ar1_rev GCAATGTCTTGGGGTTGAAA; C3: C3_fwd GCCTCTCCTCTGACCTCTGG, C3_rev AGTTCTTCGCACTGTTTCTGG; GFAP: GFAP_fwd AACCGCATCACCATTCCT, GFAP_rev CGCATCTCCACAGTCTTTACC; IL-1b: IL1b_fwd AGTTGACGGACCCCAAAAG, IL1b_rev CCACGGGAAAGACACAGG; nestin: nes_fwd GTCAGCTGAGCCTATAGTTCAACG, nes_rev AGAGTCACTCATCATTGCTGCTCC; NGF_fwd ACCACAGCCACAGACATCAA, NGF_rev GCACCCACTCTCAACAGGA; TNFa: Tnf_fwd TCCCTCCAGAAAAGACACCA, Tnf_rev CCACAAGCAGGAATGAGAA.
Statistical Analysis
Data were analyzed by two-way analysis of variance (ANOVA) with post-hoc Sidak’s test. The assumption of Gaussian distribution was assessed using Shapiro-Wilks’s test. Data are presented as mean ± SEM after normalization to both reference genes. P values < 0.05 were considered as statistically significant.
Results
C3a Down-regulates the Expression of Gfap in Astrocytes After Ischemia but Does Not Affect Astrocyte Expression of C3ar1 or Ngf
To determine the context-dependent effects of C3a on primary mouse astrocytes, we used astrocytes cultured in standard serum-free medium (naïve astrocytes), astrocytes after ischemic stress, and astrocytes exposed to LPS, an in vitro model of systemic inflammation or infection. The effects of LPS on astrocytes are indirect and mediated by microglia [17], therefore primary astrocyte cultures containing 1.8% microglia were used for all experiments.
As GFAP is one of the most commonly used markers of astrocyte reactivity [41], we first assessed the effects of C3a on the expression of Gfap. We observed that C3a reduced the expression of Gfap in astrocytes recovering after ischemic stress, with the same trend in naïve astrocytes and astrocytes exposed to LPS (Fig. 1a, d). Regardless of culture condition, C3a did not affect the expression of C3ar1 (Fig. 1b, e) or Ngf (Fig. 1c, f).
C3a Differentially Affects the Expression of C3 and Nes in Astrocytes After Ischemic and LPS Challenge
Next, we assessed the effects of C3a on the expression of C3, the product of which has been put forward as a marker of astrocytes with neurotoxic properties [17, 18]. Similar to its effect on the expression of Gfap, C3a down-regulated the expression of C3 in astrocytes after ischemic stress, but not in naïve astrocytes or astrocytes exposed to LPS (Fig. 2a, c). C3a reduced the expression of another reactive astrocyte marker Nes [42] in astrocytes after ischemic stress but increased Nes expression in astrocytes exposed to LPS. In naïve astrocytes, C3a had no effect on Nes expression (Fig. 2b, d).
C3a Increases the Expression of Tnf and Il1b in Naive Astrocytes
In naïve astrocytes, C3a increased the expression of Tnf and Il1b, coding for pro-inflammatory cytokines TNF and IL1β (Fig. 3a, b). Exposure to LPS led to dramatic increase in the expression levels of Tnf and Il1b but the expression of Tnf and Il1b in astrocytes exposed to LPS was not affected by C3a (Fig. 3c, d).
Discussion
Astrocyte responses to CNS insults are highly dependent on the pathological context [3]. Reactive astrocytes restore CNS homeostasis and neuronal functioning thus promoting functional recovery [11, 12, 16, 43] but reactive astrocytes may also contribute to maladaptive changes or inhibit neuroregeneration [4, 6, 44]. Here we show that the complement peptide C3a exerts differential effects on the expression of Gfap, C3, Nes, Tnf and Il1b in naïve astrocytes, astrocytes after ischemia and astrocytes exposed to LPS. These results demonstrate that C3a modulates astrocyte functions in a context-dependent manner, contribute to the understanding of the context-dependent roles of astrocytes and highlight the complexity of the effects of the complement system in the healthy and diseased CNS.
Diverse and even opposing functions for C3a-C3aR signaling in the CNS have been reported, including the regulation of neural plasticity [27, 29, 33, 34], neuroprotection [30,31,32], neurodegeneration [35,36,37], and dysfunction of blood–brain barrier [38]. The rather broad expression of C3aR on cells in the CNS, including neural progenitor cells [29] and mature neurons [45,46,47,48], microglia [49, 50], astrocytes [26, 45, 46], endothelial cells [38, 51, 52] and choroid plexus epithelium [53], could partly explain the broad range of effects of C3a in the brain. The context-dependent responses of neural progenitor cells [27] and astrocytes described here help to reconcile the seemingly conflicting findings on the effects of C3a-C3aR signaling in different types of CNS insults and pathologies. For example, C3aR deficiency protects mice against the loss of synapses in neuroinvasive viral infection [37] and C3aR antagonist treatment is protective against the reduction in synaptic density and dendritic complexity in neurodegeneration associated with Alzheimer’s disease [35] but has the opposite effects in the absence of any challenge [35], and intranasal treatment with C3a increases synaptogenesis in the peri-infarct region after focal ischemic injury [33]. Further, C3a-C3aR signaling may exert distinct effects at different stages after injury (e.g. acute versus post-acute or chronic phase after stroke), in different types of neurodegeneration (e.g. secondary neurodegeneration versus Alzheimer’s disease type neurodegeneration) or at different stages of a specific neurodegenerative condition. C3a-C3aR signaling thus evidently contributes to the nuancing of astrocyte phenotypes. Our findings provide additional argument against the binary division of reactive astrocytes into neurotoxic versus neuroprotective [41] and contribute to better understanding of the diversity of astrocyte phenotypes and functions.
We acknowledge that our study has some limitations. Due to the requirement for the presence of microglia in our astrocyte cultures to study the effects of C3a on astrocytes induced by LPS and the fact that C3aR is expressed by both astrocytes and microglia, the gene expression levels reported here reflect the combined response of both cell types. Although the relative contribution of microglia in the cultures was small, a robust microglial response could possibly mask an opposite effect of C3a on gene expression in astrocytes. In contrast to previous reports using enriched cultures of mouse and rat astrocytes [26, 54], which—similarly to ours—also typically contain 1–2% microglia [40, 55], we did not observe any increase in Ngf expression in astrocytes cultured in the presence of C3a. While the contribution of other cells, cell maturation stage, differences between species, as well as other differences in culture conditions could provide an explanation for this discrepancy, the effect of these factors on the net result supports the notion that the specific context plays an important role in determining astrocyte responses to C3a.
In summary, our findings show that C3a modulates astrocyte functions in a context-dependent manner and provide a potential explanation for the diverse and in some instances seemingly conflicting observations of the effects of C3a-C3aR signaling in the healthy and diseased CNS.
Data Availability
This article contains all datasets generated or analyzed during the study.
References
Verkhratsky A, Nedergaard M (2018) Physiology of astroglia. Physiol Rev 98:239–389
Pekny M, Pekna M, Messing A, Steinhäuser C, Lee JM, Parpura V, Hol EM, Sofroniew MV, Verkhratsky A (2016) Astrocytes: a central element in neurological diseases. Acta Neuropathol 131:323–345
Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA (2012) Genomic analysis of reactive astrogliosis. J Neurosci 32:6391–6410
Kinouchi R, Takeda M, Yang L, Wilhelmsson U, Lundkvist A, Pekny M, Chen DF (2003) Robust neural integration from retinal transplants in mice deficient in GFAP and vimentin. Nat Neurosci 6:863–868
Menet V, Prieto M, Privat A, Giménez y Ribotta M (2003) Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Proc Natl Acad Sci USA 100:8999–9004
Wilhelmsson U, Li L, Pekna M, Berthold CH, Blom S, Eliasson C, Renner O, Bushong E, Ellisman M, Morgan TE, Pekny M (2004) Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci 24:5016–5021
Cho K-S, Yang L, Ma HF, Lu B, Huang X, Pekny M, Chen DF (2005) Re-establishing the regenerative potential of CNS axons in postnatal mice. J Cell Sci 118:863–872
Nakazawa T, Takeda M, Lewis GP, Cho KS, Jiao J, Wilhelmsson U, Fisher SK, Pekny M, Chen DF, Miller JW (2007) Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci 48:2760–2768
Widestrand A, Faijerson J, Wilhelmsson U, Smith PL, Li L, Sihlbom C, Eriksson PS, Pekny M (2007) Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP-/- Vim-/- mice. Stem Cells 25:2619–2627
Ridge KM, Eriksson JE, Pekny M, Goldman RD (2022) Roles of vimentin in health and disease. Genes Dev 36:391–407
Li L, Lundkvist A, Andersson D, Wilhelmsson U, Nagai N, Pardo AC, Nodin C, Ståhlberg A, Aprico K, Larsson K, Yabe T, Moons L, Fotheringham A, Davies I, Carmeliet P, Schwartz JP, Pekna M, Kubista M, Blomstrand F, Maragakis N, Nilsson M, Pekny M (2008) Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 28:468–481
Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32:638–647
de Pablo Y, Nilsson M, Pekna M, Pekny M (2013) Intermediate filaments are important for astrocyte response to oxidative stress induced by oxygen-glucose deprivation and reperfusion. Histochem Cell Biol 140:81–91
Wunderlich KA, Tanimoto N, Grosche A, Zrenner E, Pekny M, Reichenbach A, Seeliger MW, Pannicke T, Perez MT (2015) Retinal functional alterations in mice lacking intermediate filament proteins glial fibrillary acidic protein and vimentin. FASEB J 29:4815–4828
Pekny M, Wilhelmsson U, Tatlisumak T, Pekna M (2019) Astrocyte activation and reactive gliosis—a new target in stroke? Neurosci Lett 689:45–55
Aswendt M, Wilhelmsson U, Wieters F, Stokowska A, Schmitt FJ, Pallast N, de Pablo Y, Mohammed L, Hoehn M, Pekna M, Pekny M (2022) Reactive astrocytes prevent maladaptive plasticity after ischemic stroke. Prog Neurobiol 209:102199
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487
Guttenplan KA, Weigel MK, Prakash P, Wijewardhane PR, Hasel P, Rufen-Blanchette U, Münch AE, Blum JA, Fine J, Neal MC, Bruce KD, Gitler AD, Chopra G, Liddelow SA, Barres BA (2021) Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature 599:102–107
Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, Barres BA (2018) Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci USA 115:E1896-e1905
Andersson D, Wilhelmsson U, Nilsson M, Kubista M, Ståhlberg A, Pekna M, Pekny M (2013) Plasticity response in the contralesional hemisphere after subtle neurotrauma: gene expression profiling after partial deafferentation of the hippocampus. PLoS ONE 8:e70699
Guttikonda SR, Sikkema L, Tchieu J, Saurat N, Walsh RM, Harschnitz O, Ciceri G, Sneeboer M, Mazutis L, Setty M, Zumbo P, Betel D, de Witte LD, Pe’er D, Studer L (2021) Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer’s disease. Nat Neurosci 24:343–354
Pekna M, Pekny M (2021) The complement system: a powerful modulator and effector of astrocyte function in the healthy and diseased central nervous system. Cells 10:1812
Pekna M, Stokowska A, Pekny M (2021) Targeting complement C3a receptor to improve outcome after ischemic brain injury. Neurochem Res 46:2626–2637
Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasak R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74:691–705
Norris GT, Smirnov I, Filiano AJ, Shadowen HM, Cody KR, Thompson JA, Harris TH, Gaultier A, Overall CC, Kipnis J (2018) Neuronal integrity and complement control synaptic material clearance by microglia after CNS injury. J Exp Med 215:1789–1801
Shinjyo N, de Pablo Y, Pekny M, Pekna M (2016) Complement peptide C3a promotes astrocyte survival in response to ischemic stress. Mol Neurobiol 53:3076–3087
Shinjyo N, Stahlberg A, Dragunow M, Pekny M, Pekna M (2009) Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 27:2824–2832
Gorelik A, Sapir T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O (2017) Developmental activities of the complement pathway in migrating neurons. Nat Commun 8:15096
Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK, Zwirner J, Wetsel RA, Gerard C, Pekny M, Pekna M (2006) Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J 25:1364–1374
van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, Fontaine M (2001) Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. NeuroReport 12:289–293
Järlestedt K, Rousset CI, Ståhlberg A, Sourkova H, Atkins AL, Thornton C, Barnum SR, Wetsel RA, Dragunow M, Pekny M, Mallard C, Hagberg H, Pekna M (2013) Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic-ischemic brain injury. FASEB J 27:3797–3804
Pozo-Rodrigálvarez A, Li Y, Stokowska A, Wu J, Dehm V, Sourkova H, Steinbusch H, Mallard C, Hagberg H, Pekny M, Pekna M (2021) C3a receptor signaling inhibits neurodegeneration induced by neonatal hypoxic-ischemic brain injury. Front Immunol 12:768198
Stokowska A, Atkins AL, Moran J, Pekny T, Bulmer L, Pascoe MC, Barnum SR, Wetsel RA, Nilsson J, Dragunow M, Pekna M (2017) Complement peptide C3a stimulates neural plasticity after experimental brain ischemia. Brain 140:353–369
Stokowska A, Pekna M (2018) Complement C3a: shaping the plasticity of the post-stroke brain. In: Lapchak PA, Zhang JH (eds) Cellular and molecular approaches to regeneration and repair, springer series in translational stroke research. Springer, Cham, pp 521–541
Lian H, Yang L, Cole A, Sun L, Chiang AC, Fowler SW, Shim DJ, Rodriguez-Rivera J, Taglialatela G, Jankowsky JL, Lu HC, Zheng H (2015) NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron 85:101–115
Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, Wang Q, Zhang B, Liu Z, Zheng H (2018) Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer’s disease. Neuron 100:1337-1353.e1335
Vasek MJ, Garber C, Dorsey D, Durrant DM, Bollman B, Soung A, Yu J, Perez-Torres C, Frouin A, Wilton DK, Funk K, DeMasters BK, Jiang X, Bowen JR, Mennerick S, Robinson JK, Garbow JR, Tyler KL, Suthar MS, Schmidt RE, Stevens B, Klein RS (2016) A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature 534:538–543
Propson NE, Roy ER, Litvinchuk A, Köhl J, Zheng H (2021) Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest 131
Pekny M, Eliasson C, Chien CL, Kindblom LG, Liem R, Hamberger A, Betsholtz C (1998) GFAP-deficient astrocytes are capable of stellation in vitro when cocultured with neurons and exhibit a reduced amount of intermediate filaments and an increased cell saturation density. Exp Cell Res 239:332–343
Wilhelmsson U, Andersson D, de Pablo Y, Pekny R, Stahlberg A, Mulder J, Mitsios N, Hortobagyi T, Pekny M, Pekna M (2017) Injury leads to the appearance of cells with characteristics of both microglia and astrocytes in mouse and human brain. Cereb Cortex 27:3360–3377
Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhäuser C, Volterra A, Carmignoto G, Agarwal A, Allen NJ, Araque A, Barbeito L, Barzilai A, Bergles DE, Bonvento G, Butt AM, Chen WT, Cohen-Salmon M, Cunningham C, Deneen B, De Strooper B, Díaz-Castro B, Farina C, Freeman M, Gallo V, Goldman JE, Goldman SA, Götz M, Gutiérrez A, Haydon PG, Heiland DH, Hol EM, Holt MG, Iino M, Kastanenka KV, Kettenmann H, Khakh BS, Koizumi S, Lee CJ, Liddelow SA, MacVicar BA, Magistretti P, Messing A, Mishra A, Molofsky AV, Murai KK, Norris CM, Okada S, Oliet SHR, Oliveira JF, Panatier A, Parpura V, Pekna M, Pekny M, Pellerin L, Perea G, Pérez-Nievas BG, Pfrieger FW, Poskanzer KE, Quintana FJ, Ransohoff RM, Riquelme-Perez M, Robel S, Rose CR, Rothstein JD, Rouach N, Rowitch DH, Semyanov A, Sirko S, Sontheimer H, Swanson RA, Vitorica J, Wanner IB, Wood LB, Wu J, Zheng B, Zimmer ER, Zorec R, Sofroniew MV, Verkhratsky A (2021) Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 24:312–325
Lin RC, Matesic DF, Marvin M, McKay RD, Brüstle O (1995) Re-expression of the intermediate filament nestin in reactive astrocytes. Neurobiol Dis 2:79–85
Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, Coppola G, Khakh BS, Deming TJ, Sofroniew MV (2016) Astrocyte scar formation aids central nervous system axon regeneration. Nature 532:195–200
Pekny M, Johansson CB, Eliasson C, Stakeberg J, Wallen A, Perlmann T, Lendahl U, Betsholtz C, Berthold CH, Frisen J (1999) Abnormal reaction to central nervous system injury in mice lacking fibrillary acidic protein and vimentin. J Cell Biol 145:503–514
Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR (1999) Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 26:201–211
van Beek J, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, Fontaine M (2000) Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 161:373–382
Benard M, Gonzalez BJ, Schouft M-T, Falluel-Morel A, Chan P, Vaudry H, Fontaine M (2004) Characterization of C3a and C5a Receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J Biol Chem 279:43487–43496
Pedersen ED, Froyland E, Kvissel AK, Pharo AM, Skalhegg BS, Rootwelt T, Mollnes TE (2007) Expression of complement regulators and receptors on human NT2-N neurons—effect of hypoxia and reoxygenation. Mol Immunol 44:2459–2468
Möller T, Nolte C, Burger R, Verkhratsky A, Kettermann H (1997) Mechanisms of C5a and C3a complement fragment-induced [Ca2+]i signaling in mouse microglia. J Neurosci 17:615–624
Heese K, Hock C, Otten U (1998) Inflammatory signals induce neurotropin expression in human microglial cells. J Neurochem 70:699–707
Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC (2003) Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 17:1003–1014
Wu F, Zou Q, Ding X, Shi D, Zhu X, Hu W, Liu L, Zhou H (2016) Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J Neuroinflamm 13:23
Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massague J (2017) Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168:1101-1113.e1113
Jauneau A-C, Ischenko A, Chatagner A, Benard M, Chan P, Schouft M-T, Patte C, Vaudry H, Fontaine M (2006) Interleukin-1β and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. J Neuroinflamm 3:8
Schildge S, Bohrer C, Beck K, Schachtrup C (2013) Isolation and culture of mouse cortical astrocytes. J Vis Exp 71:e50079
Funding
Open access funding provided by University of Gothenburg. This study was supported by grants from Swedish Research Council (2017-00991 and 2021-01486 to MPa, 2017-02255, 2019-00284 and 2020-01148 to MPy); The Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (716591 and 966011 to MPa, 724421 and 965939 to MPy); W. and M. Lundgren’s Foundation, The Swedish Brain Foundation (FO2017-0004 and FO2020-0134 to MPa, FO2018-0252 and FO2021-0082 to MPy); The Swedish Stroke Foundation (to MPa, MPy); Hagströmer’s Foundation Millennium (to MPy) and T. Söderberg’s Foundations (to MPa, MPy).
Author information
Authors and Affiliations
Contributions
Conceptualization: MPa, MPy. Data acquisition and analysis: SS, YdP, AS, ÅTN. Data interpretation: SS, YdP, AS, MPa, MPy. Figure preparation: AS. Funding acquisition: MPa, MPy. Manuscript writing: MPa, MPy. All authors read, edited, and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interest
A. Stokowska, M. Pekny, and M. Pekna hold United States and European patent patent “C3a receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders” (US 11,266,715, EP 3541402). The other authors declare no competing interests.
Ethical Approval
The protocols were approved by the Animal Ethics Committee of the University of Gothenburg, Sweden (Permit number: 41-2015).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Pekna, M., Siqin, S., de Pablo, Y. et al. Astrocyte Responses to Complement Peptide C3a are Highly Context-Dependent. Neurochem Res 48, 1233–1241 (2023). https://doi.org/10.1007/s11064-022-03743-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-022-03743-5